Market News & Trends
ARCA Biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
ARCA Biopharma, Inc. recently announced the completion of patient follow-up for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a…
Teneobio Announces Strategic Alliance With TESARO
Teneobio, Inc., a next-generation multi-specific antibody therapeutics company, recently announced the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical…
ProQR & Galapagos Announce Research Collaboration
ProQR Therapeutics N.V. recently announced it has entered into a research collaboration agreement with Galapagos N.V. Under the agreement, the two companies will work together…
CymaBay Therapeutics Receives $5-Million Milestone Payment
CymaBay Therapeutics, Inc. recently announced it has received a $5-million milestone payment from Kowa Pharmaceuticals America for the initiation of a study evaluating the pharmacokinetics…
NANOBIOTIX Partners With the Providence Cancer Institute
Nanobiotix recently announced it will begin a preclinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct…
Sanofi & Alnylam Enter Into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and…
Enable Injections Achieves ISO Certification to Meet Mounting Demand for Drug Delivery Device Combination Products
Enable Injections, Inc., developer of the advanced enFuse large volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has been awarded the International Organization…
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody
BeiGene, Ltd. recently announced that in December 2017, the first patient was dosed in a global Phase 3 clinical trial of tislelizumab, an investigational anti-PD-1…
Bellerophon Announces First Patient Enrolled in Phase 2b Study
Bellerophon Therapeutics, Inc. recently announced the first patient has been randomized into a Phase 2b study evaluating INOpulse in patients with Pulmonary Hypertension associated with…
Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies
Atara Biotherapeutics, Inc. recently announced initiation of two Phase 3 clinical studies to evaluate tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus…
GeoVax & Vaxeal to Collaborate on Cancer Immunotherapy Program
GeoVax Labs, Inc. recently announced it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program. GeoVax’s immuno-oncology program is based…
Inovio Enters License & Collaboration Agreement With ApolloBio
Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy…
Achaogen Announces FDA Acceptance of New Drug Application With Priority Review
Achaogen, Inc. recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) for plazomicin for the treatment of complicated urinary…
Secondary Packaging – How “One-Stop-Shop” Solutions Can Help Address a Changing World
By: Daniela Geiger, Vetter, Product & Service Manager In a rapidly aging world, it could be difficult for today’s pharmaceutical and biotechnology companies to…
Platform Technology Company Cell Design Labs to be Acquired by Gilead
Cell Design Labs, Inc. recently announced that Gilead Sciences has agreed to acquire them in a structured buy out valued for up to $567 million,…
LAM Therapeutics Announces Progress of its Clinical Portfolio With FDA Clearance
LAM Therapeutics, a 4Catalyzer company, advanced its clinical portfolio with the US FDA clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients.…
NRGene & Tel Aviv Sourasky Medical Center Collaborate on Parkinson’s Genomes
NRGene, the worldwide leader in genomic assembly and analysis, has partnered with the Genetic Institute of Tel Aviv Sourasky Medical Center (TASMC) to perform genomic…
RespireRx Pharmaceuticals Announces Publication of Phase 2B PACE Study
RespireRx Pharmaceuticals Inc. recently announced that the results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) clinical trial have been published by the principal…
Do's & Don'ts for Orphan Drug Support Programs
Getting personal with rare disease patients. By: Nancy Pilcher, RN, Director, Business Development, AmerisourceBergen Complex. It’s the word most often associated with the…
AMRI Doubles Bulk API Aseptic Manufacturing Capacity
AMRI, a global contract research, development, and manufacturing organization, has more than doubled its current bulk Active Pharmaceutical Ingredient (API) aseptic manufacturing capacity. The addition…
